<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171976</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002D2304</org_study_id>
    <secondary_id>2010-019795-74</secondary_id>
    <nct_id>NCT01171976</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ranibizumab in Two &quot;Treat and Extend&quot; Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus</brief_title>
  <acronym>RETAIN</acronym>
  <official_title>A 2 Year Randomized, Single-masked, Multicenter, Controlled Phase IIIb Trial Assessing the Efficacy and Safety of 0.5 mg Ranibizumab in Two &quot;Treat and Extend&quot; Treatment Algorithms vs. 0.5 mg Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that two investigational treatment regimens have
      the potential to result in a superior visual acuity improvement as compared to a ranibizumab
      pro re nata (PRN=as needed) treatment regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 24</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity of the Study Eye: Change From Baseline at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity of the Study Eye: Change From Baseline at Month 24</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 24</measure>
    <time_frame>Baseline, 24 month</time_frame>
    <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24</measure>
    <time_frame>Baseline and 24 month</time_frame>
    <description>High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Functioning Questionnaire (VFQ-25) Change From Baseline in Total Score at Month 12 and Month 24</measure>
    <time_frame>Baseline, Month 12 and Month 24</time_frame>
    <description>The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and symptoms on general health. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. Each response was recoded per the scoring rules outlined in the National Eye Institute (NEI) VFQ-25 Scoring Algorithm. Under this scoring algorithm , the recoded values range between 0 and 100 and a high score means a better functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24</measure>
    <time_frame>Baseline, Month 12 and Month 24</time_frame>
    <description>The Euro Quality of Life Questionnaire (EQ-5D) is an indirect utility questionnaire. It is a standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1= &quot;no problems&quot;, 2=&quot;some problems&quot; and 3=&quot;extreme problems&quot; . A composite health index was then defined by combining the levels for each dimension. Overall, 243 health states are possible. For each health state, the EuroQol group has assigned a utility value typically between 0 and 1 with lower scores representing a higher level of dysfunction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">373</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>TE Ranibizumab 0.5 mg and Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TE Ranibizumab 0.5 mg alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received ranibizumab intravitreal injection therapy only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRN Ranibizumab 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.</description>
    <arm_group_label>TE Ranibizumab 0.5 mg and Laser</arm_group_label>
    <arm_group_label>TE Ranibizumab 0.5 mg alone</arm_group_label>
    <arm_group_label>PRN Ranibizumab 0.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient

          -  Patients with Type 1 or Type 2 diabetes mellitus (according to American Diabetes
             Association or World Health Organization [WHO] guidelines) with glycosylated
             hemoglobin (HbA1c) ≤ 12.0% at screening (Visit 1). Patients should be on diet,
             exercise, and/or pharmacological treatment for diabetes. Treatment for diabetes must
             have been stable for at least 3 month.

        Ocular

          -  Patients with visual impairment due to DME in at least one eye who are eligible for
             laser treatment in the opinion of the investigator. If both eyes are eligible, the one
             with the worse visual acuity, as assessed at Visit 1, will be selected by the
             investigator as the study eye.

          -  BCVA ≥ 39 and ≤78 letters in the study eye and, inclusively, using Early Treatment
             Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing
             distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160) at screening.

          -  Concomitant conditions in the study eye are only permitted if, in the opinion of the
             investigator, they do not prevent improvement of visual acuity on study treatment.

        Exclusion Criteria:

        Patient Compliance/ Administrative

          -  Pregnant or nursing (lactating) women.

        Ocular medical history

          -  Active intraocular inflammation (grade trace or above) in either eye at enrollment.

          -  Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis,
             endophthalmitis) in either eye at the time of enrollment.

          -  History of uveitis in either eye at any time.

          -  Structural damage within 0.5 disc diameter of the center of the macular in the study
             eye likely to preclude improvement in visual acuity following the resolution of
             macular edema.

          -  Uncontrolled glaucoma in either eye at screening.

        Prior Ocular treatments

          -  Panretinal laser photocoagulation in the study eye within 6 months prior to
             randomization.

          -  Focal/grid laser photocoagulation in the study eye within 3 months prior to
             randomization.

          -  Treatment with anti-angiogenic drugs in either eye.

        Systemic conditions or treatments

          -  History of stroke within 6 months prior to enrollment.

          -  Renal failure requiring dialysis.

          -  Untreated diabetes mellitus.

          -  Blood pressure systolic &gt; 160 mmHg or diastolic &gt; 100 mmHg.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>505 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 6</city>
        <zip>169 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59 037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <zip>6 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heraklion Crete</city>
        <state>Crete</state>
        <zip>GR-71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>152 31</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 7</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kilkenny</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden 2333 ZA</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 EX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 BH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-354</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1150-199</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Málaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla y Leon</state>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Binningen</city>
        <zip>4102</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 2LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunderland</city>
        <zip>SR2 9HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <results_first_submitted>March 31, 2014</results_first_submitted>
  <results_first_submitted_qc>September 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2014</results_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DME</keyword>
  <keyword>Diabetic macula edema</keyword>
  <keyword>RETAIN</keyword>
  <keyword>ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 373 patients with macular edema and visual impairment secondary to DME were enrolled. A total of 372 patients were randomized. One patient was excluded from all analyses due to administrative problems</recruitment_details>
      <pre_assignment_details>Antimicrobial eye drops were dispensed at each study visit (PRN ranibizumab) or at visits with scheduled injections (TE ranibizumab + laser or TE ranibizumab alone).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TE Ranibizumad 0.5 mg and Laser</title>
          <description>Patients received an injection ranibizumab and laser therapy.</description>
        </group>
        <group group_id="P2">
          <title>TE Ranibizumab 0.5 mg Alone</title>
          <description>Patients received an intravitreal injection ranibizumab</description>
        </group>
        <group group_id="P3">
          <title>PRN Ranibizumab 0.5 mg</title>
          <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="126">Include 4 from PRN and 3 from TE alone who got laser treatment, exclude 2 with no laser treatment.</participants>
                <participants group_id="P2" count="126">Exclude 1 who did not get drug and 3 got laser treatment, include 2 from 1st arm with no laser</participants>
                <participants group_id="P3" count="118">Exclude 1 who did not get drug and 4 got laser treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test result</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Randomized Set comprised all randomized patients, ie those given a randomization number.</population>
      <group_list>
        <group group_id="B1">
          <title>TE Ranibizumad 0.5 mg and Laser</title>
          <description>Patients received an injection ranibizumab and laser therapy.</description>
        </group>
        <group group_id="B2">
          <title>TE Ranibizumab 0.5 mg Alone</title>
          <description>Patients received an intravitreal injection ranibizumab</description>
        </group>
        <group group_id="B3">
          <title>PRN Ranibizumab 0.5 mg</title>
          <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="128"/>
            <count group_id="B3" value="123"/>
            <count group_id="B4" value="372"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="9.07"/>
                    <measurement group_id="B2" value="63.0" spread="9.83"/>
                    <measurement group_id="B3" value="64.5" spread="9.66"/>
                    <measurement group_id="B4" value="63.7" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12</title>
        <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12</title>
          <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="11.50"/>
                    <measurement group_id="O2" value="64.1" spread="10.52"/>
                    <measurement group_id="O3" value="65.1" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Month 1 to Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.25" spread="11.057"/>
                    <measurement group_id="O2" value="70.28" spread="10.284"/>
                    <measurement group_id="O3" value="71.32" spread="9.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.91" spread="5.532"/>
                    <measurement group_id="O2" value="6.14" spread="5.717"/>
                    <measurement group_id="O3" value="6.20" spread="6.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 24</title>
        <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 24</title>
          <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="11.50"/>
                    <measurement group_id="O2" value="64.1" spread="10.52"/>
                    <measurement group_id="O3" value="65.1" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Month 1 to Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.12" spread="11.261"/>
                    <measurement group_id="O2" value="70.72" spread="10.924"/>
                    <measurement group_id="O3" value="72.09" spread="10.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" spread="5.986"/>
                    <measurement group_id="O2" value="6.58" spread="7.070"/>
                    <measurement group_id="O3" value="6.97" spread="6.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity of the Study Eye: Change From Baseline at Month 12</title>
        <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity of the Study Eye: Change From Baseline at Month 12</title>
          <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="11.50"/>
                    <measurement group_id="O2" value="65.1" spread="10.52"/>
                    <measurement group_id="O3" value="65.1" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.13" spread="11.945"/>
                    <measurement group_id="O2" value="70.93" spread="11.742"/>
                    <measurement group_id="O3" value="72.56" spread="11.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" spread="6.999"/>
                    <measurement group_id="O2" value="6.80" spread="8.726"/>
                    <measurement group_id="O3" value="7.44" spread="8.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity of the Study Eye: Change From Baseline at Month 24</title>
        <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity of the Study Eye: Change From Baseline at Month 24</title>
          <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="11.50"/>
                    <measurement group_id="O2" value="64.1" spread="10.52"/>
                    <measurement group_id="O3" value="65.1" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.64" spread="12.315"/>
                    <measurement group_id="O2" value="70.62" spread="13.481"/>
                    <measurement group_id="O3" value="73.18" spread="11.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.30" spread="8.129"/>
                    <measurement group_id="O2" value="6.49" spread="10.854"/>
                    <measurement group_id="O3" value="8.06" spread="8.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 12</title>
        <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 12</title>
          <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gain of &gt;= 1 letter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9"/>
                    <measurement group_id="O2" value="84.8"/>
                    <measurement group_id="O3" value="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="60.8"/>
                    <measurement group_id="O3" value="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="42.4"/>
                    <measurement group_id="O3" value="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 24</title>
        <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
        <time_frame>Baseline, 24 month</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 24</title>
          <description>Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS–like VA testing charts at a starting distance of 4 meters.</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Percentage of pateints</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gain of &gt;= 1 letter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2"/>
                    <measurement group_id="O2" value="84.0"/>
                    <measurement group_id="O3" value="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="62.4"/>
                    <measurement group_id="O3" value="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6"/>
                    <measurement group_id="O2" value="40.8"/>
                    <measurement group_id="O3" value="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="7.2"/>
                    <measurement group_id="O3" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12</title>
        <description>High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12</title>
          <description>High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.09" spread="22.992"/>
                    <measurement group_id="O2" value="-24.35" spread="22.027"/>
                    <measurement group_id="O3" value="-23.16" spread="22.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24</title>
        <description>High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.</description>
        <time_frame>Baseline and 24 month</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24</title>
          <description>High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.03" spread="25.628"/>
                    <measurement group_id="O2" value="-24.98" spread="26.414"/>
                    <measurement group_id="O3" value="-24.97" spread="26.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Functioning Questionnaire (VFQ-25) Change From Baseline in Total Score at Month 12 and Month 24</title>
        <description>The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and symptoms on general health. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. Each response was recoded per the scoring rules outlined in the National Eye Institute (NEI) VFQ-25 Scoring Algorithm. Under this scoring algorithm , the recoded values range between 0 and 100 and a high score means a better functioning</description>
        <time_frame>Baseline, Month 12 and Month 24</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Functioning Questionnaire (VFQ-25) Change From Baseline in Total Score at Month 12 and Month 24</title>
          <description>The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and symptoms on general health. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. Each response was recoded per the scoring rules outlined in the National Eye Institute (NEI) VFQ-25 Scoring Algorithm. Under this scoring algorithm , the recoded values range between 0 and 100 and a high score means a better functioning</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=116,122,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.32" spread="17.317"/>
                    <measurement group_id="O2" value="75.47" spread="17.105"/>
                    <measurement group_id="O3" value="77.07" spread="18.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 12 (n=116,122,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" spread="10.905"/>
                    <measurement group_id="O2" value="3.95" spread="10.941"/>
                    <measurement group_id="O3" value="5.41" spread="12.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at month 24 (n=116,122,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="11.859"/>
                    <measurement group_id="O2" value="2.31" spread="13.270"/>
                    <measurement group_id="O3" value="5.96" spread="12.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24</title>
        <description>The Euro Quality of Life Questionnaire (EQ-5D) is an indirect utility questionnaire. It is a standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1= “no problems”, 2=“some problems” and 3=“extreme problems” . A composite health index was then defined by combining the levels for each dimension. Overall, 243 health states are possible. For each health state, the EuroQol group has assigned a utility value typically between 0 and 1 with lower scores representing a higher level of dysfunction</description>
        <time_frame>Baseline, Month 12 and Month 24</time_frame>
        <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>TE Ranibizumad 0.5 mg and Laser</title>
            <description>Patients received an injection ranibizumab and laser therapy.</description>
          </group>
          <group group_id="O2">
            <title>TE Ranibizumab 0.5 mg Alone</title>
            <description>Patients received an intravitreal injection ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>PRN Ranibizumab 0.5 mg</title>
            <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24</title>
          <description>The Euro Quality of Life Questionnaire (EQ-5D) is an indirect utility questionnaire. It is a standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1= “no problems”, 2=“some problems” and 3=“extreme problems” . A composite health index was then defined by combining the levels for each dimension. Overall, 243 health states are possible. For each health state, the EuroQol group has assigned a utility value typically between 0 and 1 with lower scores representing a higher level of dysfunction</description>
          <population>Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" spread="17.36" lower_limit="-2.18" upper_limit="2.69"/>
                    <measurement group_id="O2" value="70.7" spread="16.10" lower_limit="-1.83" upper_limit="2.85"/>
                    <measurement group_id="O3" value="72.2" spread="13.24" lower_limit="0.25" upper_limit="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12 (n=115,123,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="16.487" lower_limit="-1.11" upper_limit="4.00"/>
                    <measurement group_id="O2" value="0.91" spread="13.422" lower_limit="-2.56" upper_limit="2.35"/>
                    <measurement group_id="O3" value="2.52" spread="14.431" lower_limit="-0.11" upper_limit="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 (n=115,123,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="17.464"/>
                    <measurement group_id="O2" value="0.11" spread="14.755"/>
                    <measurement group_id="O3" value="1.98" spread="14.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Set consisted of all patients who received at least one administration of study treatment in the study eye and had at least one post-baseline safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TE Ranibizumab 0.5 mg and Laser</title>
          <description>Patients received an injection ranibizumab and laser therapy.</description>
        </group>
        <group group_id="E2">
          <title>TE Ranibizumab 0.5 mg Alone</title>
          <description>Patients received an intravitreal injection ranibizumab</description>
        </group>
        <group group_id="E3">
          <title>PRN Ranibizumab 0.5 mg</title>
          <description>Participants received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Macular fibrosis (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vitreous adhesions (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Small intestine ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Bacterascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Endophthalmitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Endophthalmitis (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Metastases to soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diabetic macroangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.5</frequency_threshold>
        <default_vocab>16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blindness transient (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cataract (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cataract (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cataract (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctivitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Corneal disorder (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dry eye (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dry eye (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dry eye (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eye irritation (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eye pain (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eye pain (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eye pain (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eye pruritus (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eye pruritus (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eye pruritus (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eyelid oedema (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eyelid oedema (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Glaucoma (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Keratitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Lacrimation increased (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Macular fibrosis (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Macular fibrosis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Macular fibrosis (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Macular oedema (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Macular oedema (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Macular oedema (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ocular hypertension (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ocular hypertension (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Punctate keratitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Retinal exudates (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Retinal exudates (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Retinal neovascularisation (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Retinal vascular disorder (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Retinal vascular disorder (Treated non-study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Visual impairment (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vitreous floaters (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hordeolum (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Protein total increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until publication of the pooled data (i.e. data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

